Paper Details

  1. Home
  2. Paper Details

Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).

Author: GaulenZhanna, KunøeNikolaj, LatifZill-E-Huma, OpheimArild, Sharma-HaaseKamni, SolliKristin Klemmetsby, TanumLars

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This research examines the effectiveness of extended-release naltrexone (XR-NTX) for treating opioid dependence. While XR-NTX shows promise, more research is needed to understand its long-term safety and effectiveness compared to daily maintenance treatment.
Paper Details　
Original Abstract of the Article :
Current guidelines for opioid dependence recommend daily maintenance of physical dependence with methadone or buprenorphine, and discourage abstinence due to the high risk of relapse and overdose. Extended-release formulations of the opioid antagonist naltrexone (XR-NTX) block heroin and other opioi...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4848871/

データ提供：米国国立医学図書館（NLM）

Extended-Release Naltrexone vs. Daily Buprenorphine-Naloxone: A Randomized Controlled Trial

Opioid dependence is a complex and challenging issue, like navigating a desert with shifting sands and uncertain pathways. This research investigates the potential of extended-release naltrexone (XR-NTX) as a treatment option for opioid dependence, comparing it to daily buprenorphine-naloxone.

XR-NTX: A Promising Treatment Option for Opioid Dependence

The researchers propose a randomized controlled trial to compare XR-NTX with daily buprenorphine-naloxone. This trial will assess the long-term safety and effectiveness of XR-NTX in managing opioid dependence.

Navigating the Path to Opioid Recovery

This research offers hope for patients struggling with opioid dependence. XR-NTX, if proven effective, could provide a new treatment option with potentially fewer side effects and better adherence. However, it is important to consult with a healthcare professional to determine the most appropriate treatment option based on your individual needs and circumstances.

Dr. Camel's Conclusion

This research highlights the ongoing search for effective treatment options for opioid dependence. The proposed randomized controlled trial will provide valuable information about the safety and efficacy of XR-NTX. Just as a camel relies on its endurance and adaptability to navigate the desert, patients need effective treatments and support systems to overcome the challenges of opioid dependence.

Date :
  1. Date Completed 2017-10-23
  2. Date Revised 2019-01-10
Further Info :

Pubmed ID

27121539

DOI: Digital Object Identifier

PMC4848871

Related Literature

Article Analysis
・Effective treatment of opioid use
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.